GABA-B and other brain receptors as drug targets

The development of new drugs for the therapy of central nervous system (CNS) diseases  often involves identification of specific receptors for ligands thought to be involved in the pathogenesis of a disease and
search for drugs capable of modulating ligand-receptor interaction.  This approach was supported by findings that some older CNS drugs modulate binding of  neurotransmitters to their receptors.  The hope was that by improving specificity and selectivity of ligands for their receptors new and better drugs to treat CNS diseases can be found.  This approach led to a few successful CNS drugs, but failed
to cure or significantly modify the progression of Alzheimer's (AD), Parkinson's (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), schizophrenia and other major CNS diseases.  It appears that these diseases do not involve abnormal interaction of neurotransmitters with their receptors or that they are multifactorial and a ligand selective for one receptor subtype may not always represent the best approach
to the therapy of these diseases. In the videointerview witrh Dr. Greg Rose (see below)
Sam J. Enna, Professor of Molecular and Interegrative Physiology at the University of Kansas School of Medicine discusses the role of  gamma-aminobutyric acid (GABA-B) and other brain receptors in the therapy of CNS diseases.
Keywords: Gamma-aminobutyric acid (GABA); GABA-B receptors; CNS diseases; baclofen, analgesics, muscle relaxants, antidepressants; cognition enhancement; beta-adrenoceptors in CNS; muscarinic receptors, multifactorial diseases;  dimerization of the receptors; GABA-B receptors subtypes; MS; ALS; Dr. Sam J, Enna; Dr. Greg Rose.